Dramatic response of metaplastic breast cancer to chemo-immunotherapy

被引：0
|
作者：
Sylvia Adams
机构：
[1] New York University School of Medicine,
[2] Perlmutter Cancer Center,undefined
来源：
npj Breast Cancer | / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.
引用
收藏
相关论文
共 50 条
  • [41] PROLONGED SURVIVAL OF INFLAMMATORY BREAST-CANCER PATIENTS TREATED WITH COMBINED CHEMO-IMMUNOTHERAPY AND IRRADIATION
    WISEMAN, CL
    BUZDAR, AU
    GUTTERMAN, JU
    BLUMENSCHEIN, GR
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 409 - 409
  • [42] Sensitization to chemo-immunotherapy by targeting TGF-ß in preclinical triple negative breast cancer models
    Kalfeist, Laura
    Ledys, Fanny
    Petit, Stacy
    Kada-Mohammed, Samia
    Rialland, Mickael
    Ghiringhelli, Francois
    Limagne, Emeric
    Ladoire, Sylvain
    CANCER RESEARCH, 2024, 84 (06)
  • [43] Chemo-immunotherapy of breast cancer using vesiculated α-tocopheryl succinate in combination with dendritic cell vaccination
    Ramanathapuram, Lalitha V.
    Hahn, Tobias
    Dial, Sharon M.
    Akporiaye, Emmanuel T.
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2005, 53 (02): : 177 - 193
  • [44] Chemo-Immunotherapy Side Effects in Patients with Breast Cancer Referred to Outpatient Clinics in Tehran, Iran
    Mesgartehrani, Majid
    Mesgartehrani, Zeinab
    Bakhtiari, Zahra
    Shakouri, Mohammad
    Saadat, Alireza
    Ghanei, Mostafa
    Norizian, Dariush
    Mesgartehrani, Mohammad
    Shabany, Maryam
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2022, 51 (08) : 1909 - 1911
  • [45] REQUIREMENTS FOR SUCCESSFUL IMMUNOTHERAPY AND CHEMO-IMMUNOTHERAPY OF A MURINE MODEL OF OVARIAN-CANCER
    VANHAELEN, CPJ
    FISHER, RI
    CANCER RESEARCH, 1981, 41 (03) : 980 - 983
  • [46] A "bulldozer" driven by anoxic bacteria for pancreatic cancer chemo-immunotherapy
    Zhang, Huijuan
    Wang, Yaping
    Zhu, Ling
    Qi, Zijun
    Cao, Kexuan
    Chang, Junbiao
    Hou, Lin
    JOURNAL OF CONTROLLED RELEASE, 2023, 360 : 660 - 671
  • [47] TREATMENT OF BREAST-CARCINOMA RECURRENT AFTER ADJUVANT CHEMO-IMMUNOTHERAPY
    RABADI, SJ
    HAID, M
    SCANLON, EF
    KHANDEKAR, JD
    CAPRINI, JA
    OVIEDO, MA
    CUNNINGHAM, MP
    GRIZENKO, KK
    COHEN, E
    JOURNAL OF SURGICAL ONCOLOGY, 1984, 26 (04) : 233 - 237
  • [48] Intravesical chemo-immunotherapy in non muscle invasive bladder cancer
    Leopardo, D.
    Cecere, S. C.
    Di Napoli, M.
    Cavaliere, C.
    Pisano, C.
    Striano, S.
    Marra, L.
    Menna, L.
    Claudio, L.
    Perdona, S.
    Setola, S.
    Berretta, M.
    Franco, R.
    Tambaro, R.
    Pignata, S.
    Facchini, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2013, 17 (16) : 2145 - 2158
  • [49] Feasibility of combination chemo-immunotherapy (C-IT) in ovarian cancer
    Smith, L. Mary
    Schultes, Birgit C.
    Nicodemus, Christopher F.
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 872 - 873
  • [50] Biomarker-oriented chemo-immunotherapy for advanced gastric cancer
    Kono, Koji
    Nakajima, Shotaro
    Mimura, Kosaku
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (7) : 865 - 872
12345